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Aims To establish the safety, tolerability and most promising regimen of darexaban (YM150), a novel, oral, direct factor Xa
inhibitor, for prevention of ischaemic events in acute coronary syndrome (ACS).
Methods In a 26-week, multi-centre, double-blind, randomized, parallel-group study, 1279 patients with recent high-risk non-
ST-segment or ST-segment elevation ACS received one of six darexaban regimens: 5 mg b.i.d., 10 mg o.d.,
15 mg b.i.d., 30 mg o.d., 30 mg b.i.d., or 60 mg o.d. or placebo, on top of dual antiplatelet treatment. Primary
outcome was incidence of major or clinically relevant non-major bleeding events. The main efﬁcacy outcome was
a composite of death, stroke, myocardial infarction, systemic thromboembolism, and severe recurrent ischaemia.
Results Bleeding rates were numerically higher in all darexaban arms vs. placebo (pooled HR: 2.275; 95% CI: 1.13–4.60,
P ¼ 0.022). Using placebo as reference (bleeding rate 3.1%), there was a dose–response relationship (P ¼ 0.009)
for increased bleeding with increasing darexaban dose (6.2, 6.5, and 9.3% for 10, 30, and 60 mg daily, respectively),
which was statistically signiﬁcant for 30 mg b.i.d. (P ¼ 0.002). There was no decrease (indeed a numerical increase in
the 30 and 60 mg dose arms) in efﬁcacy event rates with darexaban, but the study was underpowered for efﬁcacy.
Darexaban showed good tolerability without signs of liver toxicity.
Conclusions Darexaban when added to dual antiplatelet therapy after ACS produces an expected dose-related two- to four-fold
increase in bleeding, with no other safety concerns but no signal of efﬁcacy. Establishing the potential of low-dose
darexaban in preventing major cardiac events after ACS requires a large phase III trial.
ClinicalTrials.gov Identiﬁer: NCT00994292
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The management of acute coronary syndrome (ACS) has improved
considerablyoverthepastdecades,leadingtoasubstantialdeclinein
morbidity and mortality.
1 Guidelines from the European Society of
Cardiology (ESC)
2,3 and the American College of Cardiology/
American Heart Association (ACC/AHA)
4–6 recommend the
continuation of dual antiplatelet therapy [acetylsalicylic acid (ASA)
and clopidogrel] for up to 1 year after an ACS event.
Despite this, the recurrence of ischaemic events after an ACS
event remains high, up to 9.1% at 6 months,
7 generating interest
for improved antithrombotic therapy in addition to the current
standard of antiplatelet therapy. Since thrombin plays a pivotal
role in the formation and consolidation of thrombi in ACS, there
has been interest in thrombin inhibitors, particularly as oral
forms have become available. Conventional oral anticoagulation
with vitamin K antagonists (VKAs), while effective at preventing
ischaemic events,
8 is fraught with problems related to the
narrow therapeutic range of these agents, the need for careful
monitoring, the frequent interactions with drugs and food, and
the delay in onset and offset of action.
9–12 Use of chronic triple
antithrombotic therapy with ASA, thienopyridines, and VKAs
beyond the acute phase is associated with a high risk of bleed-
ing.
13,14 In this context, more selective oral anticoagulants, direct
thrombin inhibitors such as dabigatran
15 or factor Xa (FXa) inhibi-
tors such as apixaban
16 and rivaroxaban,
17 have generated interest.
Darexaban (YM150) and its major metabolite darexaban glucur-
onide (YM-222714) are direct inhibitors of FXa. Darexaban is
rapidly absorbed from the gut and almost completely converted
into darexaban glucuronide which reaches maximum plasma levels
at 1–1.5 h post-dose and has a terminal half-life of 14–18 h. Darex-
aban glucuronide is the main active moiety driving the antithrombo-
tic effect and demonstrates a predictable pharmacokinetic (PK)/
pharmacodynamic (PD) proﬁle. Darexaban has minimal interaction
with food
18 and importantly no drug–drug interactions with
CYP3A4/P-glycoprotein inhibitors and inducers.
19 Darexaban
shows no PK or PD interaction with ASA and clopidogrel, although
the skin bleeding time increases as expected.
20 In addition, no inter-
action was observed with naproxen.
20 The drug is excreted equally
through the kidneys and faeces.
21 Since direct FXa inhibitors are
small molecules that bind to and inhibit FXa, independent of other
proteins, they are thought to bind to both clot-bound and free
FXa.
22 The potential beneﬁt of darexaban has been shown in
venous thromboembolic disease,
23,24 and has recently been
explored in the prevention of stroke in subjects with non-valvular
atrial ﬁbrillation in a phase II study (Clinical Trials.gov identiﬁer:
NCT00938730).
25–27 RUBY-1 (150-CL-201 ClinicalTrials.goviden-
tiﬁer:NCT00994292)isaphaseIItrialaimedatexploringthepoten-
tial roleof darexaban inpatientswithrecentACS, aswell asdeﬁning
a dose range in this indication.
Methods
Study objectives
The primary objective of this study was the evaluation of the safety and
tolerability of different doses and dose regimens of darexaban on top
of standard treatment with ASA with or without clopidogrel, for the
secondary prevention of ischaemic vascular events in patients with
recent ACS. The secondary objectives were the evaluation of the efﬁ-
cacy of different doses and dose regimens of darexaban on top of stan-
dard dual antiplatelet treatment in the secondary prevention of
ischaemic vascular events in patients with recent ACS, as well as
helping to deﬁne the suitable population for further development
(i.e. phase III).
Study population
Male or female patients with a diagnosis of non-ST-segment
elevation (NSTE)-ACS and high-risk features, or ST-segment
elevation (STE)-ACS were eligible for randomization. Acute coronary
syndrome was deﬁned according to accepted international guide-
lines.
3,5 If eligible, patients were randomized as early as possible
after clinical stabilization, as long as this occurred within 7 days of
presentation of the index event. In total, 1264 patients with
NSTE-ACS or STE-ACS as the index event were planned for ran-
domization. The complete inclusion and exclusion criteria are
detailed in Appendix 2.
Study design and treatments
RUBY-1 was a prospective, randomized, double-blind, multi-centre,
multiple-dose, placebo-controlled, parallel-group trial in subjects pre-
senting with ACS. Following presentation with the index ACS event,
patients were managed according to local standards of care, which
could include primary percutaneous coronary intervention (PCI),
thrombolysis, or medical management. All subjects were to receive
antiplatelet treatment as per current guidelines.
3,5 Acetylsalicylic acid
was used at a dose of 75–325 mg daily, as per local practice. The
lower dose range of ASA (i.e. 75–81 mg daily) was recommended,
or clopidogrel 75 mg daily if ASA was contraindicated or not tolerated,
or a combination of ASA 75–325 mg and clopidogrel 75 mg daily (a
maintenance dose of clopidogrel of up to 150 mg was allowed up to
7 days after the index event).
Subjects were screened for eligibility following presentation with
ACS. Once stabilized, eligible subjects were randomized, via an inter-
active voice response system, in a double-blind manner, to one of
seven parallel study treatment groups within 7 days of presentation
with the index event. The study drug was administered for a total dur-
ation of 26 weeks, in addition to standard antiplatelet treatment. Six
dose groups of darexaban and one placebo control group were eval-
uated. Randomization was stratiﬁed by country and clopidogrel use.
The allocation ratio was 1:1:1:1:1:1:2 to the following groups: darexa-
ban 5 mg b.i.d., darexaban 10 mg o.d., darexaban 15 mg b.i.d., darexa-
ban 30 mg o.d., darexaban 30 mg b.i.d., and darexaban 60 mg o.d., or
placebo. The selection of this dose range was based on previous
experience in healthy volunteers (in whom doses of up to 320 mg
for 14 days were well tolerated), as well as on prior experience in
venous thromboembolism prophylaxis,
23,24 where doses of up to
120 mg daily have been studied and were safe and effective; prior
experience in a phase II trial of stroke prevention in atrial ﬁbrillation
28
where darexaban was safe; and an indirect comparison with rivaroxa-
ban suggesting that darexaban 60 mg resulted in approximately the
same FXa inhibition as rivaroxaban 10 mg.
18 In addition, two drug–
drug interaction studies suggested no clinically relevant interaction
with ASA with or without clopidogrel.
20 Given that most ACS patients
would be on dual antiplatelet therapy, it appeared prudent to explore
the lower end of the dose range in order to study the drug at doses
that may minimize the bleeding caused by superimposition of oral
anticoagulation, which is why a daily dose of 10 mg was selected as
the starting point. Other antithrombotic drugs given for the initial man-
agement of the index event during the acute phase had to be
Ph.G. Steg et al. 2542discontinued before initiation of study treatment. Other medical treat-
ments, such as beta-blockers and angiotensin II inhibitors, were given
as per local practice and guidelines. The study was approved by the
Institutional Review Boards/Ethical Review Committees for each parti-
cipating hospital. All patients provided written informed consent prior
to randomization.
Outcome measures
Primary outcomes
The primary outcome was the incidence of major and clinically rel-
evant non-major (CRNM) bleeding events, according to a modiﬁed
version of the International Society on Thrombosis and Haemostasis
(ISTH) deﬁnition,
29 during the 6 months of the study. All overt bleed-
ing events were adjudicated by the independent adjudication commit-
tee (IAC) as either major, CRNM, or minor bleeding events. Bleeds
were also adjudicated according to the thrombolysis in myocardial
infarction (TIMI) bleeding deﬁnition.
30 Deﬁnitions of bleeding events
are detailed in Appendix 3.
Secondary outcomes
Secondary outcomes included TIMI major bleeding events, and, as the
main secondary outcome, the composite of all-cause mortality, non-
fatal myocardial infarction (MI), non-fatal stroke, and severe recurrent
ischaemia. Severe recurrent ischaemia was deﬁned as worsening
anginal symptoms lasting at least 10 min and associated with at least
two of the following: dynamic ≥0.1 mV ST depression or elevation,
hospitalization, or unplanned cardiac catheterization with evidence of
signiﬁcant coronary stenosis. Stent thromboses were also analysed
after adjudication as per the academic research consortium criteria.
31
Sample size
Assuming an incidence of major and CRNM bleeding events at
6 months of 3% for placebo and 4, 7, and 9% for darexaban 10, 30,
and 60 mg per day, respectively, a sample size of 1264 randomized sub-
jects allowed a 91% power to detect a linear trend in the mentioned
incidence vs. daily dose, using a two-sided test with 95% conﬁdence
level.
Statistical analysis
The primary analysis was performed based upon the modiﬁed
intention-to-treat data set, deﬁned as all randomized subjects who
took at least one dose of study drug. Primary and secondary vari-
ables were analysed while patients were on study treatment and 1
day after the discontinuation of treatment. Cumulative risk and
95% conﬁdence intervals (CIs) at 30 days and 6 months were calcu-
lated using Kaplan–Meier estimates. These variables were also infer-
entially analysed using a Cox regression model, using the treatment
group and antiplatelet therapy as ﬁxed effects. There was no adjust-
ment for multiple comparisons. The data analysis was generated
using SAS software (version 9.1.3; SAS Institute, Inc., Cary, NC,
USA).
Results
Patient disposition
From September 2009 to July 2010, 1279 subjects were enrolled
from 152 centres in 24 countries in Europe, the Americas, South
Africa, and Asia. The patient disposition is highlighted in Figure 1.
Overall, 1258 patients were included in the modiﬁed-intention-
to-treat data set. Patient demographics and clinical characteristics
for the overall study cohort is summarized in Table 1. The
patient demographics and clinical characteristics for all treatment
groups are summarized in Appendix 4. The majority of patients
were enrolled in Eastern European countries. Overall, the treat-
ment groups appeared comparable clinically, with a median age
of 56 years old (inter-quartile range: 50–64 years old), the majority
of patients enrolled following ST-elevation MI (71.1%) and 74.6%
had PCI for treatment of the index event. The average risk,
measured by the GRACE (Global Registry of Acute Coronary
Figure 1 Study ﬂow. b.i.d., twice daily; o.d., once daily.
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32 at presentation was similar at baseline across the
various groups, indicating that baseline risks of in-hospital and
6-month death were comparable across the groups. Since 97%
of patients were in the ASA and clopidogrel strata, results are
reported together for patients on ASA only and dual antiplatelet
therapy. Permanent discontinuation rates were 21.3% for
placebo and 23.7% for darexaban.
Bleeding
The primary safety outcome of major and/or CRNM bleeds while
on study treatment (including 1 day after treatment discontinu-
ation) is shown in Table 2 and Figure 2A and B. This primary analysis
shows that the bleeding rate was numerically higher in all darexa-
ban treatment arms than in the placebo arm, with hazard ratios
(HRs) ranging from 1.8 to 3.8. Starting with placebo as reference
(bleeding rate 3.1%), there was a dose–response relationship
(P ¼ 0.009, for trend analysed using the Cox regression model)
for increased bleeding rates with increasing darexaban dose,
since the cumulative incidence of bleeding was 6.2, 6.5, and 9.3%
for patients receiving total daily doses of 10 (n ¼ 318), 30 (n ¼
315), and 60 mg (n ¼ 306) darexaban, respectively (Figure 2B).
This increase was statistically signiﬁcant for the darexaban
30 mg b.i.d. dose (P ¼ 0.002).
The rates of bleeding were similar for patients receiving b.i.d.
(n ¼ 471) vs. o.d. (n ¼ 468) dosing with darexaban (8.4 vs. 6.1%,
respectively, P ¼ 0.310). Pooling together all dose arms of darexa-
ban (in a post hoc analysis), the primary endpoint was more
frequent with darexaban than with placebo (HR: 2.275; CI:
1.13–4.60; P ¼ 0.022).
Additional information regarding other bleeding events is
included in Table 2, reporting each component of the primary
safety outcome, and the additional outcomes of minor bleeding,
any bleeding, and bleeding categorized according to the TIMI
scheme. There were no cases of fatal bleeding or intracranial
haemorrhage in any group. All bleeding events (Figure 2A)
followed a pattern similar to that of the primary safety outcome.
Bleeding rates analysed for the entire duration of follow-up
(including the 4-week observation period following treatment
completion or premature permanent discontinuation) were
similar to results observed during the period on treatment (data
not shown).
The overall number of subjects with adverse events (AEs; which
included bleeding and efﬁcacy outcomes) was similar across the
darexaban arms and, consistent with the higher bleeding rates pre-
viously described, was slightly higher than with placebo. In addition,
AEs leading to discontinuation of the study drug were higher in the
darexaban 30 mg o.d., 30 mg b.i.d., and 60 mg o.d. arms. The per-
centage of subjects with alanine transaminase (ALT) or aspartate
transaminase (AST) .3o r.5× the upper limit of normal
(ULN) was similar across all treatment arms (Table 3). The percen-
tage of subjects with total bilirubin .2× ULN ranged from 0%
with placebo and darexaban 15 mg b.i.d. to 1.4% with darexaban
30 mg b.i.d., with no clear pattern across darexaban doses. Two
subjects, both receiving darexaban, had concurrent elevations,
one of whom had total bilirubin .3× ULN. Additionally, there
was no difference in creatinine elevations between groups (data
not shown).
Efﬁcacy
The composite of all-cause mortality, non-fatal MI, non-fatal stroke,
and severe recurrent ischaemia at 6 months was the main second-
ary outcome (Table 4) Event rates at 6 months showed no
decrease with darexaban compared with placebo. Although this
study was not powered for efﬁcacy, the cumulative incidence of
this composite efﬁcacy outcome was numerically higher in the dar-
exaban 30 and 60 mg daily dose arms compared with placebo. At
these doses, the increase appeared largely driven by severe recur-
rent ischaemia. The composite efﬁcacy outcome was infrequent
with the lowest doses of darexaban (10 mg daily arms), and
numerically lower than placebo. Other secondary efﬁcacy out-
comes are overviewed in Table 4: event rates were low and
similar between dose groups. Deﬁnite or probable stent
................................................................................
................................................................................
................................................................................
................................................................................
Table 1 Clinical characteristics of the patients
(overall study cohort)
Grand total
n 1258
Age, mean (SD) 56.9 (10.40)
Female,% 20.4
Ethnicity, n (%)
Caucasian 991 (78.8)
Black/African American 8 (0.6)
Asian 220 (17.5)
Other 39 (3.1)
Smoker, n (%)
Former 297 (23.6)
Current 531 (42.2)
Never 430 (34.2)
Hypertension, n (%) 760 (60.4)
Dyslipidaemia, n (%) 627 (49.8)
Diabetes mellitus Type 2, n (%) 277 (22.0)
Primary diagnosis for index event, n (%)
STEMI 894 (71.1)
NSTEMI 364 (28.9)
Use of PCI for index event 938 (74.6)
GRACE risk score at presentation (evaluated
population)
132.8 (n ¼ 1243)
Hx of prior CHF, n (%) 30 (2.4)
Hx of stroke/TIA, n (%) 37 (2.9)
Hx of prior MI, n (%) 150 (11.9)
Hx of CABG, n (%) 31 (2.4)
Hx of PCI, n (%) 111 (8.8)
Peripheral arterial disease, n (%) 45 (3.6)
SD, standard deviation; STEMI, ST-segment elevation; NSTEMI, non-ST-segment;
PCI, percutaneous coronary intervention; GRACE, Global Registry of Acute
Coronary Events; Hx, history; CHF, chronic heart failure; TIA, transient ischaemic
attack; MI, myocardial infarction; CABG, coronary artery bypass graft.
Ph.G. Steg et al. 2544thromboses (as per ARC criteria) occurred in 1.1% (8/703) of
patients receiving darexaban and 0.4% (1/319) of patients receiving
placebo.
Discussion
This phase II dose-ranging study showed that the frequency of
major or CRNM bleeding events during 6 months of double-blind
treatment (on top of dual antiplatelet therapy) after ACS was
two- to four-fold higher (HRs ranging from 1.8 to 3.8) with
the various doses of darexaban than with placebo. There was
an increase in bleeding rates with increasing increments in the
total daily dose. As with most phase II dose-ranging trials of
antithrombotic drugs, RUBY-1 was underpowered to study efﬁ-
cacy. There was no signal for efﬁcacy. There was no signiﬁcant
difference in the composite of non-fatal MI, non-fatal stroke,
severe recurrent ischaemia, and death due to any cause during
6 months of double-blind treatment. The incidence of these
events was numerically higher than placebo at the higher dose
range, and numerically lower at the lower end of the dose
range. However, the CIs around these point estimates were
wide. Liver safety, as measured by ALT, AST, and bilirubin
levels, appeared similar between placebo and the various doses
of darexaban.
Classic trials of VKAs added to single antiplatelet therapy with
ASA have demonstrated superior efﬁcacy compared with antipla-
telet therapy alone in secondary prevention after ACS,
33,34
although this was achieved at the expense of an increased risk of
major bleeding.
8,34 However, VKAs have a narrow therapeutic
margin, a slow onset and offset of action, and numerous food
and drug interactions, and, therefore, require careful monitoring.
New oral anticoagulants targeting thrombin or factor X have
been designed to overcome these problems, and darexaban is par-
ticularly attractive in this setting given its predictable PK proper-
ties
18 and minimal potential for drug–drug interactions.
19,20
Indeed, there is evidence from several phase II studies
15–17,35
that adding an oral anticoagulant to antiplatelet therapy in patients
with recent ACS may have some efﬁcacy in the prevention of
ischaemic events and death compared with antiplatelet therapy
alone, and this concept has led to several phase III trials.
36,37
However, even with novel anticoagulants that have a broader
therapeutic margin than VKAs, the selection of dose is critical for
................................................................. ..............................................................
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...............................................................................................................................................................................
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Table 2 Safety outcomes
Placebo KM
rate (n/N)
Total daily
darexaban dose
Once daily dosing Twice daily dosing
KM rate (n/N) HR (95% CI) vs.
placebo
P-value KM rate (n/N) HR (95% CI) vs.
placebo
P-value
Primary safety endpoint—Kaplan–Meier analysis of the cumulative risk of major and clinically relevant non-major bleeding events
3.1% (9/319)
10 mg 5.6% (8/159) 1.775 (0.68, 4.60) 0.238 6.8% (9/159) 2.045 (0.81, 5.15) 0.129
30 mg 5.6% (8/156) 1.831 (0.71, 4.75) 0.213 7.5% (10/159) 2.269 (0.92, 5.59) 0.075
60 mg 7.3% (10/153) 2.425 (0.98, 5.97) 0.054 11.3% (15/153) 3.796 (1.66, 8.68) 0.002
Darexaban,
5 mg b.i.d.
(n 5 159)
Darexaban,
10 mg o.d.
(n 5 159)
Darexaban,
15 mg b.i.d.
(n 5 159)
Darexaban,
30 mg o.d.
(n 5 156)
Darexaban,
30 mg b.i.d.
(n 5 153)
Darexaban,
60 mg o.d.
(n 5 153)
Placebo
(n 5 319)
Absolute event rates for individual categories of bleeding events
Major and
CRNM
9 (5.7) 8 (5.0) 10 (6.3) 8 (5.1) 15 (9.8) 10 (6.5) 9 (2.8)
Major 1 (0.6) 1 (0.6) 2 (1.3) 3 (1.9) 3 (2.0) 0 (0.0) 1 (0.3)
CRNM 8 (5.0) 7 (4.4) 8 (5.0) 5 (3.2) 13 (8.5) 10 (6.5) 8 (2.5)
Minor 13 (8.2) 12 (7.5) 16 (10.1) 12 (7.7) 17 (11.1) 16 (10.5) 18 (5.6)
Any 21 (13.2) 18 (11.3) 24 (15.1) 20 (12.8) 30 (19.6) 23 (15.0) 26 (8.2)
TIMI bleeding events
Major 1 (0.6) 1 (0.6) 0 (0.0) 3 (1.9) 1 (0.7) 0 (0.0) 1 (0.3)
Minor 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Requiring
medical
attention
8 (5.0) 6 (3.8) 9 (5.7) 5 (3.2) 13 (8.5) 10 (6.5) 6 (1.9)
Insigniﬁcant 13 (8.2) 13 (8.2) 16 (10.1) 14 (9.0) 19 (12.4) 16 (10.5) 20 (6.3)
Any 21 (13.2) 18 (11.3) 24 (15.1) 20 (12.8) 30 (19.6) 23 (15.0) 26 (8.2)
All data are n (%); KM, Kaplan–Meier; HR, hazard ratio; CI, conﬁdence interval, b.i.d., twice daily; o.d, once daily; CRNM, clinically relevant non-major; TIMI, thrombolysis in
myocardial infarction.
RUBY-1: a trial of darexaban following ACS 2545secondary prevention after ACS, because in this setting (in which
most patients have received coronary stents) dual antiplatelet
therapyispartofthestandardofcareandisrecommendedbyguide-
lines.
2,3,5 Indeed, in the present study, 95% of patients were on dual
antiplatelettherapy,contrastingwithpriorstudieswithVKAs,which
were performed before the era of dual antiplatelet therapy after
ACS. Therefore, adding an anticoagulant would result in long-term
triple antithrombotic therapy, which may result in unacceptable
bleeding, and indicates that this strategy would need to show a tan-
gible efﬁcacy beneﬁt, with a reduction in cardiovascular death, MI,
and stroke, to offset any bleeding hazard. In fact, a large phase III
trialofapixabaninthissettingwasrecentlystoppedduetoincreased
bleeding which was not offset by increased efﬁcacy,
37 and
development of another FXa inhibitor in ACS was halted after a
phase II study.
38 Another phase III trial with rivaroxaban after
ACS
36 is ongoing and is expected to be reported on later this year.
This trial will be key in understanding whether the concept of
adding an oral anticoagulant to standard of care dual antiplatelet
therapy in order to prevent recurrent events after ACS is valid or
whether in the current environment of potent antiplatelet therapy,
this can only result in increased bleeding without compensatory
reductions in thrombotic/ischaemic endpoints.
Darexaban has been previously studied in human volunteers
18–
20 and in patients with venous thromboembolism or atrial ﬁbrilla-
tion for the prevention of stroke.
23–28 It provides reliable inhi-
bition of FXa and shows no unexpected safety concerns. Given
Figure 2 (A) Kaplan–Meier analysis of the cumulative risk of major and clinically relevant non-major bleeding (black bars), and any bleeding
events (white bars) at 6 months (safety analysis set). (B) Kaplan–Meier analysis of the cumulative risk of the primary safety endpoint of major
and clinically relevant non-major bleeding events for the three total daily doses of darexaban (10, 30, and 60 mg). Cumulative incidences are
calculated using Kaplan–Meier estimates and presented as relative to 1 (e.g. 0.06 represents 6%). CRNM, clinically relevant non-major; b.i.d.,
twice daily; o.d., once daily.
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Table 3 Overview of adverse events, including liver-related clinical laboratory abnormalities during the treatment period
Darexaban,
5 mg b.i.d.
(n 5 159)
Darexaban,
10 mg o.d.
(n 5 159)
Darexaban,
15 mg b.i.d.
(n 5 159)
Darexaban,
30 mg o.d.
(n 5 156)
Darexaban
30 mg b.i.d.
(n 5 153)
Darexaban
60 mg o.d.
(n 5 153)
Darexaban, all
(n 5 939)
Placebo
(n 5 319)
Adverse events (%) 100 (62.9) 102 (64.2) 100 (62.9) 96 (61.5) 101 (66.0) 99 (64.7) 598 (63.7) 181 (56.7)
AEs leading to
discontinuation (%)
16 (10.1) 25 (15.7) 21 (13.2) 27 (17.3) 29 (19.0) 25 (16.3) 95 (10.1) 31 (9.7)
ALT or AST .3×
ULN
5/143 (3.5) 4/149 (2.7) 2/148 (1.4) 1/138 (0.7) 2/139 (1.4) 2/137 (1.5) 16/854 (1.9) 7/290 (2.4)
ALT or AST .5×
ULN
2/149 (1.3) 2/155 (1.3) 0 (0.0) 0 (0.0) 1/146 (0.7) 1/144 (0.7) 6/909 (0.7) 2/302 (0.7)
Total bilirubin .2×
ULN
1/150 (0.7) 1/151 (0.7) 0 (0.0) 1/147 (0.7) 2/141 (1.4) 1/141 (0.7) 6/889 (0.7) 0 (0.0)
Total bilirubin .3×
ULN
0 (0.0) 1/151 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1/931 (0.1) 0 (0.0)
All data are n (%); b.i.d., twice daily; o.d., once daily; AE, adverse event; ALT, alanine transaminase; AST, aspartate transaminase; ULN, upper limit of normal.
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Table 4 Efﬁcacy outcomes
Darexaban,
5 mg b.i.d.
(n 5 159)
Darexaban,
10 mg o.d.
(n 5 159)
Darexaban,
15 mg b.i.d.
(n 5 159)
Darexaban,
30 mg o.d.
(n 5 156)
Darexaban,
30 mg b.i.d.
(n 5 153)
Darexaban,
60 mg o.d.
(n 5 153)
Darexaban, all
(n 5 939)
Placebo
(n 5 319)
Kaplan–Meier analysis of cumulative risk of composite of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, and severe recurrent ischaemia
Cumulative risk 4.3 4.3 7.4 7.3 6.9 9.3 6.5 5.2
95% CI 2.0–9.4 2.0–9.4 4.0–13.3 4.0–13.1 3.6–12.9 5.4–15.8 5.0–8.5 3.1–8.6
Absolute frequencies and proportions of secondary efﬁcacy endpoints at 6 months
Non-fatal MI, non-fatal stroke,
severe recurrent ischaemia
and all deaths, n (%)
6 (3.8) 6 (3.8) 10 (6.3) 10 (6.4) 9 (5.9) 12 (7.8) 53 (5.6) 14 (4.4)
Non-fatal MI, non-fatal stroke,
and all deaths n (%)
4 (2.5) 5 (3.1) 4 (2.5) 5 (3.2) 5 (3.3) 4 (2.6) 27 (2.9) 7 (2.2)
Deaths, n (%) 0 (0.0) 2 (1.3) 0 (0.0) 3 (1.9) 1 (0.7) 1 (0.7) 7 (0.7) 2 (0.6)
MI, n (%) 4 (2.5) 4 (2.5) 4 (2.5) 5 (3.2) 4 (2.6) 4 (2.6) 25 (2.7) 6 (1.9)
Severe recurrent ischaemia,
n (%)
2 (1.3) 1 (0.6) 6 (3.8) 5 (3.2) 4 (2.6) 8 (5.2) 26 (2.8) 7 (2.2)
Stroke, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
TIA, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.7) 2 (0.2) 0 (0.0)
STE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
In each row, only the ﬁrst event is counted, however, patients may be counted in more than one row. All data are n (%) unless otherwise stated; b.i.d., twice daily; o.d., once daily; CI, conﬁdence interval; MI, myocardial infarction; TIA, transient
ischaemic attack; STE, systemic thromboembolic event.
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8the concerns regarding bleeding associated with long-term triple
oral antithrombotic therapy, the observation in RUBY-1 that
bleeding increases with dose suggests that a phase III trial of dar-
exaban after ACS should use doses at the lower end of the dose
range (e.g. 10 mg daily). The lower doses of darexaban are
expected to result in an increased risk of bleeding, as shown in
this study, but may provide sufﬁcient FXa inhibition to result in
an efﬁcacy beneﬁt. Prior studies with other FXa antagonists
have previously shown that they may have a ﬂat dose–response,
as seen in a phase II dose-ranging trial of fondaparinux after
ACS,
39 in which the lowest doses appeared to be associated
with the lowest rates of bleeding but no beneﬁt in increasing
the dose in terms of efﬁcacy. There was no efﬁcacy signal in
RUBY-1, even though the trial was underpowered for efﬁcacy.
Given the failure of FXa inhibition to add beneﬁt to dual antipla-
telet therapy after ACS in the APPRAISE-2 trial, the validity of the
concept of combining dual antiplatelet therapy with anticoagulant
therapy after ACS remains at best uncertain. The likelihood of the
success of a phase III trial with darexaban will need to be placed
in the context of the results of ongoing trials like ATLAS
ACS-2.
17,36
As with any clinical trial, results from this study should be inter-
preted with consideration of the potential limitations. This study
had limited power to detect differences in efﬁcacy between the
various dose groups and placebo, as is clear from the wide CIs
of the point estimates of the event rates. However, efﬁcacy
results from phase II studies in this setting have been documented
as unreliable, with encouraging phase II results not conﬁrmed in
phase III
16,37 and apparently neutral phase II studies being followed
by resounding efﬁcacy in properly powered phase III trials.
40–42
This study does, however, provide clear information and guidance
regarding the tolerability of darexaban, in terms of bleeding, when
added as a third antithrombotic agent to treatment with ASA and
clopidogrel, as well as the fact that the relative risks of bleeding are
consistent regardless of the severity and bleeding scale used.
Another limitation of this study is that it is only relevant to treat-
ment when added on top of ASA and clopidogrel. The safety of
darexaban when combined with more potent P2Y12 antagonists
such as prasugrel
43 or ticagrelor
42 is unknown. Given the superior-
ity of these agents over clopidogrel after ACS, the potential clinical
efﬁcacy beneﬁt of adding darexaban to dual antiplatelet therapy
may be reduced and the bleeding risk increased when ASA is com-
bined with either of these new agents. Generalizability of results is
always an important consideration in trials, and even though the
majority of patients were enrolled in Eastern Europe, our study
has broad geographical representation with enrolment in 24
countries over four continents, including India and South Africa.
In addition, the trial enrolled a relatively young and low-risk
patient population, with a predominance of STEMI. The bleeding
rates observed may not necessarily be representative of bleeding
rates, which might be expected in a less selected, older patient
population, with more comorbidities. The trial has pooled
together STE-ACS and NSTE-ACS, which may have introduced
further heterogeneity, although current recommendations for sec-
ondary prevention with antithrombotics are identical for both con-
ditions,
2–5 and many prior trials of antithrombotics in this setting
have done so.
15–17,35–37,42,43
Conclusion
Darexaban, when added to dual antiplatelet therapy after ACS
(including patients who have undergone PCI), produces an
expected dose-related two- to four-fold increase in bleeding.
While the trial was underpowered to study efﬁcacy, there was
no reduction in the composite efﬁcacy outcome, which was
numerically higher than placebo at the higher dose range and
numerically lower at the lower dose range. Establishing the poten-
tial of low-dose darexaban in preventing major cardiac events after
ACS would require a large phase III trial to test whether it might
achieve clinical efﬁcacy on top of dual antiplatelet therapy
without an unacceptable increase in the risk of bleeding.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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Inclusion criteria—all needed to be fulﬁlled for a patient to be eligible for the study
18 years of age or older
Diagnosis of STE-ACS or NSTE-ACS as index event
Elevated cardiac biomarkers (Troponin T or I, or CK-MB) .2× ULN for CK-MB or .ULN for Troponin
For subjects with a diagnosis of NSTE-ACS, at least one of the following additional risk factors for ischaemic events had to be present:
ST deviation on ECG at any time between presentation and randomization
Age 65 years of age or older
Previous ACS ,12 months prior to randomization
Multi-vessel coronary artery disease
Ischaemic stroke or TIA at least 12 months prior to randomization
Type 2 diabetes mellitus
Peripheral arterial disease
Clinicallystable (deﬁned as discontinuation of parenteral antithrombotics and not likely to requirereinstitution of parenteral antithrombotics at the time
of randomization) and receiving current standard oral antiplatelet therapy
Able to be randomized within 7 days after presentation. Subjects should be randomized as soon as possible after discontinuation of parenteral
antithrombotics
Has provided Institutional Review Board-/Independent Ethics Committee-approved written informed consent and privacy language as per national
regulations or informed consent has been obtained from the legally authorized representative prior to any study-related procedures
Main exclusion criteria
Need for ongoing therapy with parenteral or oral anticoagulants, thrombolytics, glycoprotein IIb/IIIa antagonists, or other antiplatelet drugs
Patient plannedformyocardialrevascularizationoranyotherinvasive procedurewith increasedriskforbleeding(i.e. elective surgical procedures)within
60 days
Active bleeding or, in the opinion of the investigator, high risk of bleeding during the study
Recent stroke or TIA ,12 months prior to index event
Bleeding diathesis or any other condition or laboratory abnormality with increased tendency for bleeding (e.g. platelet count ,100000/mL)
Female of childbearing potential who refuses to use a medically acceptable form of contraception throughout the study
Female who is pregnant or lactating
Persistent SBP of 160 mmHg or higher and/or DBP of 100 mmHg or higher at baseline with or without medication
Hepatic insufﬁciency or ALT .2.0 times the ULN or total bilirubin .1.5 times the ULN
Renal creatinine clearance of ,60 mL/min (Cockcroft–Gault equation)
Any concurrent illness which may interfere with treatment or evaluation of safety or completion of this study
Participation in another clinical trial within 30 days
Participation in any darexaban clinical trials
Known allergy to the study drug or any of its components
STE-ACS, ST segment elevation ACS; ACS, acute coronary syndrome; NSTE-ACS, non-ST segment elevation ACS; CK, creatine kinase; ULN, upper limit of normal; ECG,
electrocardiogram; TIA, transient ischaemic attack; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALT, alanine transaminase.
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Appendix 3: Deﬁnitions of bleeding events
Type of bleeding Deﬁnition
Major bleeding Fatal bleeding, clinically overt bleeding associated with a decrease in the haemoglobin level of .2 g/dL (1.24 mmol/L) compared
with the pre-bleeding level, clinically overt bleeding leading to transfusion of two or more units of whole blood or packed cells,
and symptomatic bleeding in a critical area or organ, such as retroperitoneal, intracranial, intraocular, intra-spinal, intra-articular,
pericardial, or intramuscular bleeding with compartment syndrome
CRNM bleeding Any bleeding event considered as clinically relevant by the IAC that did not meet the criteria of a major bleeding event, e.g. any
bleeding event that required medical attention or any bleeding requiring discontinuation of blinded study drug treatment
All other bleeding
events
Those events not fulﬁlling the criteria of major or CRNM bleeding events. In addition, transfusions and the reasons behind them
were tracked, and for each bleeding episode, an adjusted decrease in haemoglobin was computed by adding the number of units
of packed red blood cells transfused to the decrease in haemoglobin
CRNM, clinically relevant non-major; IAC, independent adjudication committee.
Appendix 4: Clinical characteristics of the patients
Variable Darexaban,
5 mg b.i.d.
Darexaban,
10 mg o.d.
Darexaban,
15 mg b.i.d.
Darexaban,
30 mg o.d.
Darexaban,
30 mg b.i.d.
Darexaban,
60 mg o.d.
Placebo
n 159 159 159 156 153 153 319
Age, mean (SD) 57.4 (10.43) 57.1 (10.35) 56.3 (9.58) 56.1 (10.05) 57.2 (11.53) 55.7 (10.39) 57.5 (10.44)
Female,% 20.8 21.4 18.2 16.0 21.6 17.0 24.1
Ethnicity, n (%)
Caucasian 124 (78.0) 123 (77.4) 124 (78.0) 126 (80.8) 117 (76.5) 120 (78.4) 257 (80.6)
Black/African
American
2 (1.3) 4 (2.5) 1 (0.6) 0 (0.0) 1 (0.7) 0 (0.0) 0 (0.0)
Asian 27 (17.0) 28 (17.6) 30 (18.9) 26 (16.7) 28 (18.3) 27 (17.6) 54 (16.9)
Other 6 (3.8) 4 (2.5) 4 (2.5) 4 (2.6) 7 (4.6) 6 (3.9) 8 (2.5)
Enrolment region, n (%)
Europe 108 (67.9) 108 (67.9) 108 (67.9) 108 (69.2) 104 (68.0) 105 (68.6) 219 (68.7)
North America 9 (5.7) 7 (4.4) 7 (4.4) 8 (5.1) 7 (4.6) 7 (4.6) 15 (4.7)
Central/South
America
11 (6.9) 13 (8.2) 11 (6.9) 10 (6.4) 12 (7.8) 11 (7.2) 24 (7.5)
Asia/Paciﬁc/South
Africa
31 (19.5) 31 (19.5) 33 (20.8) 30 (19.2) 30 (19.6) 30 (19.6) 61 (19.1)
Smoker, n (%)
Former 42 (26.4) 34 (21.4) 31 (19.5) 33 (21.2) 33 (21.6) 41 (26.8) 83 (26.0)
Current 69 (43.4) 65 (40.9) 68 (42.8) 63 (40.4) 62 (40.5) 64 (41.8) 140 (43.9)
Never 48 (30.2) 60 (37.7) 60 (37.7) 60 (38.5) 58 (37.9) 48 (31.4) 96 (30.1)
Hypertension, n (%) 90 (56.6) 99 (62.3) 95 (59.7) 91 (58.3) 95 (62.1) 96 (62.7) 194 (60.8)
Dyslipidaemia, n (%) 77 (48.4) 74 (46.5) 77 (48.4) 89 (57.1) 76 (49.7) 81 (52.9) 153 (48.0)
Diabetes mellitus
Type 2, n (%)
39 (24.5) 37 (23.3) 37 (23.3) 43 (27.6) 34 (22.2) 27 (17.6) 60 (18.8)
Continued
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Appendix 4: (Continued)
Variable Darexaban,
5 mg b.i.d.
Darexaban,
10 mg o.d.
Darexaban,
15 mg b.i.d.
Darexaban,
30 mg o.d.
Darexaban,
30 mg b.i.d.
Darexaban,
60 mg o.d.
Placebo
Primary diagnosis for index event, n (%)
STEMI 111 (69.8) 121 (76.1) 119 (74.8) 106 (67.9) 108 (70.6) 109 (71.2) 220 (69.0)
NSTEMI 48 (30.2) 38 (23.9) 40 (25.2) 50 (32.1) 45 (29.4) 44 (28.8) 99 (31.0)
Use of PCI for index
event
122 (76.7) 116 (73.0) 119 (74.8) 115 (73.7) 118 (77.1) 113 (73.9) 235 (73.7)
Standard antiplatelet therapy, n (%)
With clopidogrel 154 (96.9) 152 (95.6) 152 (95.6) 152 (97.4) 148 (96.7) 148 (96.7) 309 (96.9)
Without
clopidogrel
5 (3.1) 7 (4.4) 7 (4.4) 4 (2.6) 5 (3.3) 5 (3.3) 10 (3.1)
Time from index
event to ﬁrst dose
(mean days)
4.1 4.0 4.3 3.8 4.1 4.2 4
GRACE risk score at
presentation
(evaluated
population)
132.6
(n ¼ 158)
134.7
(n ¼ 156)
135.1
(n ¼ 156)
130.6
(n ¼ 154)
132.3
(n ¼ 152)
131.2
(n ¼ 153)
132.8
(n ¼ 314)
Hx of prior CHF,
n (%)
4 (2.5) 3 (1.9) 6 (3.8) 2 (1.3) 3 (2.0) 4 (2.6) 8 (2.5)
Hx of stroke/TIA,
n (%)
3 (1.9) 4 (2.5) 4 (2.5) 8 (5.1) 6 (3.9) 6 (3.9) 6 (1.9)
Hx of prior MI, n (%) 19 (11.9) 9 (5.7) 17 (10.7) 24 (15.4) 18 (11.8) 18 (11.8) 45 (14.1)
Hx of CABG, n (%) 8 (5.0) 3 (1.9) 1 (0.6) 5 (3.2) 3 (2.0) 5 (3.3) 6 (1.9)
Hx of PCI, n (%) 10 (6.3) 8 (5.0) 13 (8.2) 13 (8.3) 22 (14.4) 20 (13.1) 25 (7.8)
Peripheral arterial
disease, n (%)
9 (5.7) 4 (2.5) 6 (3.8) 5 (3.2) 4 (2.6) 4 (2.6) 13 (4.0)
Premature
permanent
study drug
discontinuation,
n (%)
30 (18.9) 31 (19.5) 32 (20.1) 44 (28.2) 50 (32.7) 36 (23.5) 68 (21.3)
Duration of drug
exposure, median
weeks (Q1, Q3)
26.0
(23.9, 26.1)
26.0
(24.3, 26.1)
26.0
(19.6, 26.1)
26.0
(20.6, 26.1)
25.7
(11.6, 26.1)
26.0
(17.7, 26.1)
26.0
(25.0, 26.1)
Concomitant medications, n (%)
Beta-blockers 146 (91.8) 147 (92.4) 149 (93.7) 145 (92.9) 139 (90.8) 133 (86.9) 293 (91.8)
ACE-inhibitors 128 (80.5) 126 (79.2) 121 (76.1) 117 (75.0) 123 (80.4) 116 (75.8) 248 (77.7)
Angiotensin
receptor
blockers
17 (11.0) 23 (14.5) 25 (15.7) 17 (10.9) 19 (12.4) 23 (15.0) 43 (13.5)
Statins 150 (94.3) 154 (96.9) 156 (98.1) 146 (93.6) 146 (95.4) 145 (94.8) 304 (95.3)
Fibrates 4 (2.5) 6 (3.8) 3 (1.9) 5 (3.2) 2 (1.3) 5 (3.3) 10 (3.1)
PPIs 50 (31.4) 49 (30.8) 47 (29.6) 67 (42.9) 63 (41.2) 60 (39.2) 99 (31.0)
Variable Darexaban,
b.i.d.
Darexaban,
o.d.
Darexaban,
10 mg doses
Darexaban,
30 mg doses
Darexaban,
60 mg doses
Darexaban,
total
Grand total
n 471 468 318 315 306 939 1258
Age, mean (SD) 57.0 (10.52) 56.3 (10.26) 57.2 (10.37) 56.2 (9.80) 56.5 (10.98) 56.6 (10.39) 56.9 (10.4)
Female, % 20.2 18.2 21.1 17.1 19.3 19.2 20.4
Ethnicity, n (%)
Caucasian 365 (77.5) 369 (78.8) 247 (77.7) 250 (79.4) 237 (77.5) 734 (78.2) 991 (78.8)
Black/African
American
4 (0.8) 4 (0.9) 6 (1.9) 1 (0.3) 1 (0.3) 8 (0.9) 8 (0.6)
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Appendix 4: (Continued)
Variable Darexaban,
b.i.d.
Darexaban,
o.d.
Darexaban,
10 mg
doses
Darexaban,
30 mg
doses
Darexaban,
60 mg
doses
Darexaban,
total
Grand total
Asian 85 (18.0) 81 (17.3) 55 (17.3) 56 (17.8) 55 (18.0) 166 (17.7) 220 (17.5)
Other 17 (3.6) 14 (3.0) 10 (3.1) 8 (2.5) 13 (4.2) 31 (3.3) 39 (3.1)
Enrolment region, n (%)
Europe 320 (67.9) 321 (68.6) 216 (67.9) 216 (68.6) 209 (68.3) 641 (68.3) 860 (68.4)
North America 23 (4.9) 22 (4.7) 16 (5.0) 15 (4.8) 14 (4.6) 45 (4.8) 60 (4.8)
Central/South
America
34 (7.2) 34 (7.3) 24 (7.5) 21 (6.7) 23 (7.5) 68 (7.2) 92 (7.3)
Asia/Paciﬁc/South
Africa
94 (20.0) 91 (19.4) 62 (19.5) 63 (20.0) 60 (19.6) 185 (19.7) 246 (19.6)
Smoker, n (%)
Former 106 (22.5) 108 (23.1) 76 (23.9) 64 (20.3) 74 (24.2) 214 (22.8) 297 (23.6)
Current 199 (42.3) 192 (41.0) 134 (42.1) 131 (41.6) 126 (41.2) 391 (41.6) 531 (42.2)
Never 166 (35.2) 168 (35.9) 108 (34.0) 120 (38.1) 106 (34.6) 334 (35.6) 430 (34.2)
Hypertension, n (%) 280 (59.4) 286 (61.1) 189 (59.4) 186 (59.0) 191 (62.4) 566 (60.3) 760 (60.4)
Dyslipidaemia, n (%) 230 (48.8) 244 (52.1) 151 (47.5) 166 (52.7) 157 (51.3) 474 (50.5) 627 (49.8)
Diabetes mellitus
Type 2, n (%)
110 (23.4) 107 (22.9) 76 (23.9) 80 (25.4) 61 (19.9) 217 (23.1) 277 (22.0)
Primary diagnosis for index event, n (%)
STEMI 338 (71.8) 336 (71.8) 232 (73.0) 225 (71.4) 217 (70.9) 674 (71.8) 894 (71.1)
NSTEMI 133 (28.2) 132 (28.2) 86 (27.0) 90 (28.6) 89 (29.1) 265 (28.2) 364 (28.9)
Use of PCI for index
event, n (%)
359 (76.2) 344 (73.5) 238 (74.8) 234 (74.3) 231 (75.5) 703 (74.9) 938 (74.6)
Standard antiplatelet therapy, n (%)
With clopidogrel 454 (96.4) 452 (96.6) 306 (96.2) 304 (96.5) 296 (96.7) 906 (96.5) 1215 (96.6)
Without
clopidogrel
17 (3.6) 16 (3.4) 12 (3.8) 11 (3.5) 10 (3.3) 33 (3.5) 43 (3.4)
Time from index
event to ﬁrst dose
(mean days)
4.2 4.0 4.1 4.1 4.1 4.1 4.1
GRACE risk score at
presentation
(evaluated
population)
133.3
(n ¼ 466)
132.2
(n ¼ 463)
133.6
(n ¼ 314)
132.9
(n ¼ 310)
131.8
(n ¼ 305)
132.8
(n ¼ 929)
132.8
(n ¼ 1243)
Hx of prior CHF,
n (%)
13 (2.8) 9 (1.9) 7 (2.2) 8 (2.5) 7 (2.3) 22 (2.3) 30 (2.4)
Hx of stroke/TIA,
n (%)
13 (2.8) 18 (3.8) 7 (2.2) 12 (3.8) 12 (3.9) 31 (3.3) 37 (2.9)
Hx of prior MI, n (%) 54 (11.5) 51 (10.9) 28 (8.8) 41 (13.0) 36 (11.8) 105 (11.2) 150 (11.9)
Hx of CABG, n (%) 12 (2.5) 13 (2.8) 11 (3.5) 6 (1.9) 8 (2.6) 25 (2.7) 31 (2.5)
Hx of PCI, n (%) 45 (9.6) 41 (8.8) 18 (5.7) 26 (8.3) 42 (13.7) 86 (9.2) 111 (8.8)
Peripheral arterial
disease, n (%)
19 (4.0) 13 (2.8) 13 (4.1) 11 (3.5) 8 (2.6) 32 (3.4) 45 (3.6)
Premature
permanent study
drug
discontinuation,
n (%)
112 (23.8) 111 (23.7) 61 (19.2) 76 (24.1) 86 (28.1) 223 (23.7) 291 (23.1)
Duration of drug
exposure, median
weeks (Q1,Q3)
26.0
(19.1, 26.1)
26.0
(21.9, 26.1)
26.0
(24.1, 26.1)
26.0
(19.6, 26.1)
26.0
(13.1, 26.1)
26.0
(20.0, 26.1)
26.0
(22.0, 26.1)
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Appendix 4: (Continued)
Variable Darexaban,
b.i.d.
Darexaban,
o.d.
Darexaban,
10 mg
doses
Darexaban,
30 mg
doses
Darexaban,
60 mg
doses
Darexaban,
total
Grand total
Concomitant medications, n (%)
Beta-blockers 434 (92.1) 425 (90.8) 293 (92.1) 294 (93.3) 272 (88.9) 859 (91.5) 1152 (91.6)
ACE-inhibitors 372 (79.0) 359 (76.7) 254 (79.9) 238 (75.6) 239 (78.1) 731 (77.8) 979 (77.8)
Angiotensin
receptor
blockers
61 (13.0) 63 (13.5) 40 (12.6) 42 (13.3) 42 (13.7) 124 (13.2) 167 (13.3)
Statins 452 (96.0) 445 (95.1) 304 (95.6) 302 (95.9) 291 (95.1) 897 (95.5) 1201 (95.5)
Fibrates 9 (1.9) 16 (3.4) 10 (3.1) 8 (2.5) 7 (2.3) 25 (2.7) 35 (2.8)
PPIs 160 (34.0) 176 (37.6) 99 (31.1) 114 (36.2) 123 (40.2) 336 (35.8) 435 (34.6)
SD, standard deviation; STEMI, ST-segment elevation; NSTEMI, non-ST-segment; PCI, percutaneous coronary intervention; GRACE, Global Registry of Acute Coronary Events;
Hx, history; CHF, chronicheart failure;TIA,transient ischaemic attack; MI, myocardial infarction; CABG, coronaryartery bypass graft;PPI, proton pump inhibitor; Q, quartile; ACE,
angiotensin-converting enzyme.
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